19 November 2026

New report tracks the rising cost of medicines for Australian households

A new report commissioned by AbbVie finds Australians are paying more out of pocket for prescription medicines, while government PBS investment per person has fallen. It’s a useful read for anyone supporting patients through the cost of cancer treatment.

Cost comes up often in cancer care conversations, from non-PBS treatments to the slow build-up of everyday scripts. A new report puts some numbers to what many patients are experiencing.

State of the Nation: Medicines Access in Australia is an economic and policy analysis by Insight Economics, commissioned and funded by AbbVie Australia. Insight Economics was responsible for the methodology, analysis and conclusions. The report finds that Australians are paying substantially more towards prescription medicines than they did two decades ago, and that people on lower incomes spend a higher proportion of household income on medicines.

The numbers

  • After adjusting for inflation, household spending on private prescriptions and PBS co-payments was 64% higher in 2024 than in 2006. Per person, that means individuals are paying 23% more out of pocket. 
  • Between FY06 and FY25, inflation-adjusted government PBS spending per person (excluding supply chain and dispensing costs) fell by 26%, from $376 to $280 per person per year. 
  • The access gap spans common and chronic conditions, including cancer, cardiovascular disease, diabetes, dementia, inflammatory bowel disease and migraine. 
  • More than 150 stakeholders contributed, including patients and clinicians. 

Why it matters for cancer nurses

  • We all know that financial strain is part of many people’s cancer experience. Data like this can help frame conversations about costs and when to bring in social work or financial counselling.
  • The finding that lower-income households carry a heavier relative burden is a reminder to ask about costs early, not just when someone mentions them.

The report calls for reform, including reinvesting savings from PBS reforms to support access to new medicines. Because it was commissioned by a pharmaceutical company, it’s worth reading alongside other perspectives on PBS reform.

Read the report